Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Regulatory News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Clinigen Group plc

2 Nov 2017 15:20

RNS Number : 4310V
BlackRock Group
02 November 2017
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

(a) Full name of discloser:

BlackRock, Inc.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Clinigen Group plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

01 November 2017

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

0.1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,829,279

1.58%

0

0.00%

(2) Cash-settled derivatives:

 

37,570

0.03%

0

0.00%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00%

0

0.00%

 

TOTAL:

1,866,849

1.61%

0

0.00%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

0.1p ordinary

CFD

Reducing long

2,833

GBP 11.7091

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None.

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None.

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

Date of disclosure:

02 November 2017

Contact name:

Andrew Manchester

Telephone number:

+44 20 7743 3650

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETLLFISLLLFIID
Date   Source Headline
10th Jun 202011:00 amRNSIssue of Equity
5th Jun 20204:19 pmRNSDirector/PDMR Shareholding
26th May 20202:39 pmRNSUpdate on 2019 AGM resolution vote
1st May 20208:00 amRNSAppointment of Nominated Adviser and Joint Broker
16th Apr 20207:00 amRNSExclusive licensing agreement and trading update
24th Mar 20207:00 amRNSPurchase of shares and PDMR notification
11th Mar 20209:11 amRNSHolding(s) in Company
6th Mar 20207:54 amRNSHolding(s) in Company
28th Feb 20202:55 pmRNSHolding(s) in Company
25th Feb 20207:00 amRNSHalf Year Results
4th Feb 20209:00 amRNSNotification of half year results
16th Jan 20207:00 amRNSHalf Year Trading Update
14th Jan 20207:00 amRNSAgreement with Iovance to supply Proleukin®
4th Dec 20199:28 amRNSGrant of share options and PDMR notification
26th Nov 201910:53 amRNSResult of AGM
31st Oct 20199:46 amRNSTotal Voting Rights
29th Oct 201911:18 amRNSGrant of share options and PDMR notification
16th Oct 201910:12 amRNSIssue of Equity
3rd Oct 20197:00 amRNSAnnual Report and Accounts and notice of AGM
19th Sep 201912:37 pmRNSDirector/PDMR Shareholding
19th Sep 20197:00 amRNSInternational platform taking shape
5th Aug 201911:00 amRNSNotification of full year results date
16th Jul 20197:00 amRNSYear end trading update
28th Jun 201911:00 amRNSTotal Voting Rights
26th Jun 20197:00 amRNSMHRA licenses two Melatonin products
3rd Jun 20199:00 amRNSIssue of Equity
28th May 20196:02 pmRNSHolding(s) in Company
15th May 20197:00 amRNSUS commercial rights of Ethyol® and Totect®
2nd Apr 20197:00 amRNSClinigen completes US Proleukin rights acquisition
29th Mar 20192:40 pmRNSGrant of share options and PDMR notification
27th Feb 20197:00 amRNSHalf Year Results
25th Feb 20193:45 pmRNSHolding(s) in Company
13th Feb 20197:00 amRNSClinigen to acquire US rights to Proleukin®
12th Feb 20197:00 amRNSNotification of half year results date
5th Feb 201910:00 amRNSAppointment of CFO
15th Jan 20197:00 amRNSHalf Year trading update
30th Nov 20182:55 pmRNSIssue of Equity
28th Nov 20187:00 amRNSCapital Markets Day
15th Nov 20189:00 amRNSBoard Appointment
8th Nov 20183:39 pmRNSResult of AGM
31st Oct 20189:00 amRNSTotal Voting Rights
9th Oct 201810:12 amRNSClinigen Completes Acquisition of iQone Healthcare
9th Oct 20187:00 amRNSAnnual Report and Accounts, and notice of AGM
2nd Oct 20184:59 pmRNSClinigen Group Completes Acquisition of CSM
1st Oct 20183:29 pmRNSDirector/PDMR Shareholding
27th Sep 20184:37 pmRNSResult of Placing
27th Sep 20187:02 amRNSClinigen acquires iQone Healthcare Holding
27th Sep 20187:00 amRNSClinigen Group Proposed Placing up to £80m
27th Sep 20187:00 amRNSClinigen Group agreed acquisition of CSM
27th Sep 20187:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.